ODYSSEY OUTCOME (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab) randomized trial demonstrated that PCSK9 inhibitor alirocumab reduced Lp(a) by a median 23.5% after 4 months (29). The gene discussed is PCSK9; the disease is acute coronary syndrome.